Another Arcalyst Trial May Be Regeneron’s Best Path To Approval In Gout
Executive Summary
Recommending against approval, FDA’s Arthritis Advisory Committee says there is not enough data for Regeneron’s gout therapy and suggests that chronic and refractory populations should be studied.